282 542

Cited 25 times in

Updated treatment strategies for intestinal Behcet's disease

DC Field Value Language
dc.contributor.author박용은-
dc.contributor.author천재희-
dc.date.accessioned2018-08-28T16:45:20Z-
dc.date.available2018-08-28T16:45:20Z-
dc.date.issued2018-
dc.identifier.issn1226-3303-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161904-
dc.description.abstractBehcet's disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor alpha are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association of Internal Medicine-
dc.relation.isPartOfKOREAN JOURNAL OF INTERNAL MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleUpdated treatment strategies for intestinal Behcet's disease-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYong Eun Park-
dc.contributor.googleauthorJae Hee Cheon-
dc.identifier.doi10.3904/kjim.2017.377-
dc.contributor.localIdA04571-
dc.contributor.localIdA04030-
dc.relation.journalcodeJ02883-
dc.identifier.eissn2005-6648-
dc.identifier.pmid29207867-
dc.subject.keywordAdalimumab-
dc.subject.keywordBiological products-
dc.subject.keywordInfliximab-
dc.subject.keywordIntestinal Behcet disease-
dc.subject.keywordTumor necrosis factor-alpha-
dc.contributor.alternativeNamePark, Yong Eun-
dc.contributor.alternativeNameCheon, Jae Hee-
dc.contributor.affiliatedAuthorPark, Yong Eun-
dc.contributor.affiliatedAuthorCheon, Jae Hee-
dc.citation.volume33-
dc.citation.number1-
dc.citation.startPage43119-
dc.identifier.bibliographicCitationKOREAN JOURNAL OF INTERNAL MEDICINE, Vol.33(1) : 43119, 2018-
dc.identifier.rimsid59495-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.